<DOC>
	<DOCNO>NCT01048580</DOCNO>
	<brief_summary>This Phase I study Perifosine + Capecitabine patient advance colon cancer .</brief_summary>
	<brief_title>Study Perifosine + Capecitabine Colon Cancer Patients</brief_title>
	<detailed_description>This study Phase I trial . A total 3 ‐ 9 patient enrol . Three patient initially enrol . There dose escalation study one dose perifosine ( 50 mg ) combination one dose capecitabine ( 1000 mg/m2 BID ) evaluate . The maximum tolerated dose ( MTD ) define few 33 % patient experience DLT attributable study drug ( ) , least six patient treat dose evaluable toxicity . Pharmacokinetic ( PK ) data also evaluate enrolled patient .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients 3rd line &gt; metastatic colon cancer Patients must receive candidate regimens contain 5‐ FU , oxaliplatin , irinotecan , bevacizumab , cetuximab panitumumab No prior exposure perifosine Adequate bone marrow , liver , renal function Patients must least one measurable lesion Patients must agree extra blood drawn PK analyse Patients prior exposure perifosine . Patients receive investigational agent device . History allergic reaction attribute compound similar chemical biologic composition perifosine ( miltefosine edelfosine ) . Patients know dipyrimidine dehydrogenase ( DPD ) deficiency prior severe reaction 5‐FU . Patients known central nervous system CNS metastasis . Patients know HIV , Hepatitis B , Hepatitis C seropositivity . Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement . Patients history unstable newly diagnose angina pectoris , recent myocardial infarction ( within 6 month enrollment ) , New York Heart Association class II‐IV congestive heart failure . Female patient pregnant lactate ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Perifosine</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Colon Cancer</keyword>
</DOC>